Diligence memo · auto-generated · as of July 3, 2026

Tamarind Bio, Inc.

Tamarind Bio, Inc. has raised $14M over 1 round; too few niche peers to rank its valuation yet.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Tamarind Bio, Inc. operates in Biotech, based in SAN FRANCISCO, CA, USA. AI Inference Platform for Drug Discovery

Sub-sector tags: AI-powered Drug Discovery, Artificial Intelligence, B2B, Biotech, SaaS, ai/ml, devtools, pharma.

Capital & rounds (filed)filed

Tamarind Bio, Inc. has raised $14M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $14M on 2025-05-02.

Most recent recorded round closed around 2025-05-02.

Valuation (modeled)modeled

Provath models Tamarind Bio, Inc. at approximately $48M (range $15M–$85M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Too few comparable companies in this niche to rank the valuation fairly yet.

Financing rhythm & timingmixed

Last raise 14 mo ago; this sector typically re-raises about every 11 months.

Slightly overdue versus sector cadence.

Comparablesmixed

Capital scale ranks ahead of 87% of Biotech peers (233 compared).

Modeled value ranks above 82% of those peers.

Closest niche peers: CHD Bioscience, Inc..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.